The company name arises from cardiac and autonomic, referring to the heart and the autonomic nervous system. The name signifies how this therapy enables the heart to optimize patient health.
Cardionomic treats reduced cardiac output – ADHF’s root cause – by neuromodulating the terminal branches of the cardiac plexus to benignly increase contractility.
Beyond simply relieving dyspnea¹ as current therapies do, Cardionomic’s acute, non-systemic therapy will improve cardiac output, renal blood flow, urine production and pharmacological tolerance. Concurrently the therapy also achieves the associated decreases in plasma norepinephrine (NE) and B-type natriuretic peptide (BNP), which are objective biomarkers of chronic heart failure.
Cardionomic’s on-going activities have demonstrated many key aspects of this approach in appropriate populations and is rapidly progressing to demonstrate the ability to avoid worsening heart failure, improve inpatient symptoms and reduce in-hospital mortality. Our therapy is also expected to improve oral medication tolerance at discharge, thus reducing readmissions and mortality.
The Cardionomic Difference
1. Baig MK, Mahon N, McKenna WJ, Caforio AL, Bonow RO, Francis GS, et al. The pathophysiology of advanced heart failure. Am Heart J 1998;135:S216e30
CAUTION: INVESTIGATIONAL DEVICE LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE.
©2021 Cardionomic, Inc. All Rights Reserved.